Who are Azopt's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): dorzolamide/timolol, ACETAZOLAMIDE oral capsule, Drug: dorzolamide/timolol, Dorzolamide 2% drops, treatment with dorzolamide/timolol, dorzolamide/timolol maleate fixed combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brinzolamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Azopt — Competitive Intelligence Brief

Azopt (BRINZOLAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic Anhydrase Inhibitor [EPC]. Area: Cardiovascular.

marketed Carbonic Anhydrase Inhibitor [EPC] carbonic anhydrase II Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Azopt (BRINZOLAMIDE) — Novartis. Brinzolamide reduces intraocular pressure by inhibiting carbonic anhydrase II, decreasing aqueous humor secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Azopt TARGET	BRINZOLAMIDE	Novartis	marketed	Carbonic Anhydrase Inhibitor [EPC]	carbonic anhydrase II	1998-01-01
dorzolamide/timolol	dorzolamide/timolol	CT Glaucoma Associates	marketed	Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination	Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2)
ACETAZOLAMIDE oral capsule	ACETAZOLAMIDE oral capsule	University of Zurich	marketed	Carbonic anhydrase inhibitor	Carbonic anhydrase II
Drug: dorzolamide/timolol	Drug: dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Carbonic anhydrase inhibitor / Beta-blocker combination	Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2)
Dorzolamide 2% drops	Dorzolamide 2% drops	University Health Network, Toronto	marketed	Carbonic anhydrase inhibitor	Carbonic anhydrase II
treatment with dorzolamide/timolol	treatment with dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Carbonic anhydrase inhibitor / Beta-blocker combination	Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2)
dorzolamide/timolol maleate fixed combination	dorzolamide/timolol maleate fixed combination	Pharmaceutical Research Network	marketed	Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination	Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic Anhydrase Inhibitor [EPC] class)

· 1 drug in this class
Novartis · 1 drug in this class
Teva · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azopt — Competitive Intelligence Brief. https://druglandscape.com/ci/brinzolamide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab